The University of MichiganNews Services
The University Record Online
search
Updated 9:00 AM April 15, 2009
 

record update


front

accolades

briefs

view events

submit events

UM employment


obituaries
police beat
regents round-up
research reporter
letters


archives

Advertise with Record

contact us
meet the staff
contact us

  Research
High-dose radiation improves rate of lung cancer survival

Higher doses of radiation combined with chemotherapy improve survival in patients with stage III lung cancer, according to a new study by researchers at the Comprehensive Cancer Center.

Standard treatment for this stage of lung cancer — when the tumor is likely too large to be surgically removed — involves a combination of radiation therapy with chemotherapy.

But, the new study finds, giving chemotherapy at the same time as the radiation enhances the effect of both. Further, increasing the dose of radiation over the course of treatment also increased survival.

"When patients are diagnosed with stage III lung cancer, surgery is often not an option, and survival rates are typically quite low. Finding new ways to improve survival, even in small increments, is crucial," says senior study author Dr. Feng-Ming Kong, associate professor of radiation oncology at the Medical School and chief of radiation oncology at the Ann Arbor Veteran's Administration Healthcare System.

The study, published in the April 1 issue of the International Journal of Radiation Oncology*Biology*Physics, looked at 237 patients who had been treated for stage III, non-small cell lung cancer at U-M and the VA Ann Arbor.

The researchers compared survival among patients treated with radiation alone, with radiation followed by chemotherapy, and with radiation and chemotherapy given at the same time. Thirty-one of the patients also were enrolled in a study in which the radiation dose was increased throughout the course of the treatment.

Patients treated with radiation alone had the worst overall survival rates, living an average 7.4 months after diagnosis.

Adding chemotherapy increased survival to 14.9 months when it was administered after completing radiation, and 15.8 months when administered at the same time as radiation.

After five years, 19.4 percent of the patients receiving concurrent chemotherapy were still alive, compared to 7.5 percent of patients receiving sequential chemotherapy.

"Our study shows chemotherapy helps, and high-dose radiation helps. But it's challenging to administer these treatments at the same time because of the potential toxicity associated with the high-dose radiation," Kong says.

Additional authors are Dr. Li Wang, Dr. Candace R. Correa, Dr. Lujun Zhao, Dr. James Hayman, Dr. Gregory Kalemkerian, Dr. Susan Lyons, Dr. Kemp Cease, and Dr. Dean Brenner.

More Stories